Shots: Fitbit launched the Fitbit Heart Study, which focuses to validate the use of its wearables to detect AFib. The virtual study is open to Fitbit users aged 22yrs. + with a current Fitbit device and will enroll hundreds of thousands of people with its results supporting the Company’s regulatory submissions globally Fitbit’s devices use […]Read More
Shots: Janssen is reimagining digital clinical trial design with the launch of a CHIEF-HF study. The study will evaluate Invokana (canagliflozin) vs PBO in patients aged ≥18yrs. with either preserved or reduced ejection fraction HF, with or without T2D The CHIEF HF study will utilize personal smartphones and wearable devices to track patient outcomes via […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
